|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NIS in cancer patients has primarily been recorded to be a cytoplasmic protein, thus limiting the scope for targeted radio-iodine therapy.
|
31455607 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Making use of the tumoral TGFB1 signaling network in the context of MSC-mediated NIS gene delivery is a promising approach to foster tumor stroma-selectivity of NIS transgene expression and tailor NIS-based gene therapy to TGFB1-rich tumor environments.
|
30121623 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased expression of the cell surface receptor c-Met, the glucose transporter GLUT-1 and the sodium iodide symporter lead to tumour growth, angiogenesis and cell migration.
|
30819129 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent studies have described important roles for the sodium iodide symporter (NIS) in tumor behavior.
|
30191346 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination of EBRT and SMAD-NIS-MSC-mediated <sup>131</sup>I therapy resulted in a significantly improved delay in tumor growth and prolonged survival in therapy mice as compared with the combined therapy using CMV-NIS-MSCs or to control groups receiving EBRT or saline only, or EBRT together with SMAD-NIS-MSCs and saline applications.
|
31196853 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Ultimately, combining BLI and NIS imaging represented a significant enhancement over traditional BLI, providing more information about tumor size and location.
|
30674994 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the dual-targeting approach highlights the benefits of a bifunctional strategy for a future clinical translation of the bioimaging-based NIS-mediated radiotherapy allowing efficient targeting of heterogeneic tumors with variable receptor expression levels.
|
30683895 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Active MSC recruitment into the tumor stroma was confirmed using NIS immunohistochemistry (IHC).
|
30224540 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhancement of <sup>211</sup>At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer.
|
30796173 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Sodium Iodide Symporter (NIS), responsible for active transport of iodide into thyroid cells, allows the use of radioactive iodine (RAI) as the systemic treatment of choice for TC metastatic disease.
|
31590142 |
2019 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sodium/iodide symporter (NIS)-mediated iodide uptake plays an important physiological role in regulating thyroid gland function, as well as in diagnosing and treating Graves' disease and thyroid cancer.
|
31331356 |
2019 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhancement of <sup>211</sup>At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer.
|
30796173 |
2019 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sodium/iodide symporter (NIS)-mediated iodide uptake plays an important physiological role in regulating thyroid gland function, as well as in diagnosing and treating Graves' disease and thyroid cancer.
|
31331356 |
2019 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Sodium Iodide Symporter (NIS), responsible for active transport of iodide into thyroid cells, allows the use of radioactive iodine (RAI) as the systemic treatment of choice for TC metastatic disease.
|
31590142 |
2019 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These preliminary data suggest that assessment of the NIS expression and EMT phenotypes of CTCs may serve as potential adjuncts for predicting and monitoring the curative effect of RAI therapy in DTC patients and avoid ineffective treatment.Further validation is warranted.
|
31147861 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, this study shows the important role of mannosidase in N-glycosylation processing in order to correctly traffic NIS to the plasma membrane in breast cancer cells.This article has an associated First Person interview with the first author of the paper.
|
31455607 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We further engineered MSCs to express the sodium iodide symporter (<i>NIS</i>) reporter gene under control of a hypoxia-responsive promoter and the vascular endothelial growth factor (VEGF) promoter to test effects on these pathways <i>in vitro</i> and, for VEGF, <i>in vivo</i> in an orthotopic hepatocellular carcinoma (HCC) xenograft mouse model by positron emission tomography imaging.
|
31816265 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that external beam radiotherapy (EBRT) results in the enhanced recruitment of <i>NIS-</i>expressing MSCs into human hepatocellular carcinoma (HuH7).
|
31196853 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The dual-targeting approach was used to deliver the theranostic sodium iodide symporter (NIS) gene to hepatocellular cancer.
|
30683895 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
123I-scintigraphy revealed significant tumor-specific radioiodide accumulation and thus NIS expression after systemic application of SMAD-NIS-MSCs into mice harboring subcutaneous tumors derived from the human hepatocellular carcinoma (HCC) cell line HuH7, which express TGFB1.
|
30121623 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We transfected the HCC cells (Huh7) with NIS gene, designated as Huh7/NIS, and isolated the EVs from them.
|
30880979 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies evaluating the etiological roles of these factors in linking breast and thyroid cancer might also improve our understanding and identify new therapeutic approaches, such as sodium/iodide symporter-mediated radioiodine therapy and thyroid-stimulating hormone receptor antagonists, for breast cancer.
|
29976206 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors.
|
28228086 |
2018 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In summary, our results elucidate a pump-independent, protumorigenic role for NIS in thyroid cancer via its cross-talk with PTEN signaling.<b>Significance:</b> A novel pump-independent protumorigenic role of nonmembranous NIS challenges the presumption that radioiodine treatment of thyroid cancer is ineffective when transmembrane NIS is not expressed.<i>Cancer Res; 78(21); 6121-33.©2018 AACR</i>.
|
30217930 |
2018 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
|
29978611 |
2018 |